Literature DB >> 23686806

Overexpression of CRKL correlates with malignant cell proliferation in breast cancer.

Tingting Zhao1, Zhifeng Miao, Zhenning Wang, Yingying Xu, Jianhua Wu, Xingyu Liu, Yi You, Jiguang Li.   

Abstract

Crk-like (CRKL) is an adapter protein that has crucial roles in multiple biological processes, including cell proliferation, adhesion, and migration. However, the expression pattern of CRKL protein and its clinical significance in human breast cancers have not been well characterized. In this study, expression of CRKL was evaluated in 108 human invasive ductal carcinoma (IDC) tissues by immunohistochemistry. CRKL protein was upregulated in the cancer tissues compared with adjacent normal mammary glands. Overexpression of CRKL was found in 40 of 108 (37.03 %) breast cancer samples and correlated with advanced p-tumor-node-metastasis stage (p = 0.002), nodal metastasis (p = 0.0323), and tumor size (p = 0.0075). In addition, overexpression of CRKL in the MDA-MB-435 cell line promoted cell proliferation, and small interfering RNA knockdown of CRKL in the MDA-MB-453 cell line inhibited proliferation. Further analysis of cell cycle-related molecules showed that CRKL induced cyclin D1 and phosphorylated extracellular signal-regulated kinase expression. In conclusion, this study demonstrated that overexpression of CRKL correlated with progression and malignant proliferation of human breast cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686806     DOI: 10.1007/s13277-013-0851-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

1.  Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition.

Authors:  Christian F Singer; Gernot Hudelist; Wolfgang Lamm; Ruth Mueller; Claudia Handl; Ernst Kubista; Klaus Czerwenka
Journal:  Oncol Rep       Date:  2006-02       Impact factor: 3.906

2.  Detection of SH3-binding proteins in total cell lysates with glutathione S-transferase-SH3 fusion proteins: SH3 blot assay.

Authors:  S M Feller; B Knudsen; T W Wong; H Hanafusa
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

3.  Expression of the molecular chaperone αB-crystallin in infiltrating ductal breast carcinomas and the significance thereof: an immunohistochemical and proteomics-based strategy.

Authors:  Maria Kabbage; Mounir Trimeche; Hela Ben Nasr; Philippe Hammann; Lauriane Kuhn; Bechr Hamrita; Anouar Chaieb; Lotfi Chouchane; Karim Chahed
Journal:  Tumour Biol       Date:  2012-09-13

Review 4.  Cyclin D1 and breast cancer.

Authors:  Pankaj G Roy; Alastair M Thompson
Journal:  Breast       Date:  2006-05-03       Impact factor: 4.380

5.  Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.

Authors:  Yan Wang; Qian-ze Dong; Ling Fu; Maggie Stoecker; Endi Wang; En-Hua Wang
Journal:  Mol Carcinog       Date:  2012-06-29       Impact factor: 4.784

Review 6.  Crk family adaptors-signalling complex formation and biological roles.

Authors:  S M Feller
Journal:  Oncogene       Date:  2001-10-01       Impact factor: 9.867

7.  Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.

Authors:  Mohamed Elfagieh; Fathi Abdalla; Asma Gliwan; Jamela Boder; Wafa Nichols; Abdelbaset Buhmeida
Journal:  Tumour Biol       Date:  2012-09-05

8.  An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment.

Authors:  Paul J Mintz; Marina Cardó-Vila; Michael G Ozawa; Amin Hajitou; Roberto Rangel; Liliana Guzman-Rojas; Dawn R Christianson; Marco A Arap; Ricardo J Giordano; Glauco R Souza; Jeffrey Easley; Ahmad Salameh; Salvatore Oliviero; Ricardo R Brentani; Erkki Koivunen; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-23       Impact factor: 11.205

9.  CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.

Authors:  R Salgia; N Uemura; K Okuda; J L Li; E Pisick; M Sattler; R de Jong; B Druker; N Heisterkamp; L B Chen
Journal:  J Biol Chem       Date:  1995-12-08       Impact factor: 5.157

10.  Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer.

Authors:  Y H Kim; K A Kwei; L Girard; K Salari; J Kao; M Pacyna-Gengelbach; P Wang; T Hernandez-Boussard; A F Gazdar; I Petersen; J D Minna; J R Pollack
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

View more
  10 in total

1.  The association of Crk-like adapter protein with poor prognosis in glioma patients.

Authors:  Chengjun Yao; Shunzeng Lv; Mingzhi Han; Jie Zhang; Ya Zhang; Li Zhang; Ruiyang Yi; Dongxiao Zhuang; Jinsong Wu
Journal:  Tumour Biol       Date:  2014-02-22

2.  Clinical significance and biological roles of CRKL in human bladder carcinoma.

Authors:  Bin Han; Lan Luan; Zhenqun Xu; Bin Wu
Journal:  Tumour Biol       Date:  2013-12-28

3.  The clinical implications of Crk-like adaptor protein expression in papillary thyroid microcarcinoma.

Authors:  Xiangshan Yang; Wenyuan Lv; Ranran Shi; Shaomei Cheng; Jing Zhang; Zhongfa Xu
Journal:  Tumour Biol       Date:  2014-09-04

4.  CRKL oncogene is downregulated by p53 through miR-200s.

Authors:  Miyuki Tamura; Yasushi Sasaki; Kenta Kobashi; Kousuke Takeda; Takafumi Nakagaki; Masashi Idogawa; Takashi Tokino
Journal:  Cancer Sci       Date:  2015-07-14       Impact factor: 6.716

5.  Crk-like adapter protein is overexpressed in cervical carcinoma, facilitates proliferation, invasion and chemoresistance, and regulates Src and Akt signaling.

Authors:  Hong Ji; Bo Li; Shitai Zhang; Zheng He; Yang Zhou; Ling Ouyang
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

6.  CRKL overexpression promotes cell proliferation and inhibits apoptosis in endometrial carcinoma.

Authors:  Le Cai; He Wang; Qing Yang
Journal:  Oncol Lett       Date:  2016-11-17       Impact factor: 2.967

7.  Proteomic and functional characterization of intra-tumor heterogeneity in human endometrial cancer.

Authors:  M Fairuz B Jamaluddin; Yi-An Ko; Arnab Ghosh; Shafiq M Syed; Yvette Ius; Rachel O'Sullivan; Jacob K Netherton; Mark A Baker; Pravin Nahar; Kenneth Jaaback; Pradeep S Tanwar
Journal:  Cell Rep Med       Date:  2022-09-13

8.  HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL.

Authors:  Xuehai Bian; Zhongxing Liang; Amber Feng; Eric Salgado; Hyunsuk Shim
Journal:  Biochem Pharmacol       Date:  2017-12-01       Impact factor: 6.100

9.  LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.

Authors:  Jochen J Frietsch; Carolin Kastner; Thomas G P Grunewald; Hardy Schweigel; Peter Nollau; Janine Ziermann; Joachim H Clement; Paul La Rosée; Andreas Hochhaus; Elke Butt
Journal:  Oncotarget       Date:  2014-07-30

Review 10.  Crk and CrkL as Therapeutic Targets for Cancer Treatment.

Authors:  Taeju Park
Journal:  Cells       Date:  2021-03-27       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.